Respira Therapeutics has issued a press release to introduce its drug engine technology (DET) dry powder inhaler, which the company says “can be deployed and optimized in short test cycles with a wide range of compounds.” The company is claiming that the novel mechanism of the inhaler delivers at high efficiencies never before achieved.
According to Respira President of Discovery and Clinical Development Jacques Pappo, “Respira Therapeutics offers an unprecedented clinical benefit for combination therapy in the treatment of patients with compromised lung function, e.g., moderate and severe COPD where the patients’ inspiratory energy is insufficient to derive therapeutic benefit from currently available inhaled medications. We have consistently found superior performance, in the ranges of 3-4-fold, when compared with available competitor products for these respiratory disease indications.”
The press release includes comment from scientific advisory board member John Dixon, who says, “Respira technology brings an ingenious and imaginative approach suitable for a range of agents for respiratory indications. Capacity is not compromised whilst efficiency of delivery is enhanced. In the case of combinations, the different drugs do not need to be stored together but are combined at the point of delivery with a simplicity absent in other approaches. Early results are most encouraging.”
Respira received initial funding from the Cottonwood Technology Fund in October 2010. The management team includes Pappo, Brian Windsor of Enavail, and Hugh Smyth of the University of Texas, Austin.
Read the Respira press release.
